menu ☰
menu ˟

Merck halts development of anacetrapib

12 Oct 2017
Merck has announced that applications will not be submitted for regulatory approval of anacetrapib, a cholesteryl ester transfer protein inhibitor for the treatment of patients with CVD.Numerous studies have shown that anacetrapib not only raises HDL...

Click here to view the full article which appeared in Cardiology

Please note

The news articles accessible on the Health Well website have been compiled from various sources that are not controlled by the Institute of Public Health in Ireland (IPH). IPH is therefore not responsible for the content of external websites and the inclusion of a link to an external website from the Health Well should not be understood to be an endorsement of that website.